Ridgeline Therapeutics, Inc.
Houston, TX
- UEI
- KM9RHDLMHTN5
- CAGE
- 6PN60
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 3778 Georgetown St, Houston, TX 77005, USA
- Website
- ridgelinetherapeutics.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older… | National Institute on Aging | $3,584,245 | |
| Transformative drugs to prevent osteoarthritis and speed recovery following traumatic joint injury in military and… | Defense Health Agency | $498,988 | |
| A novel small molecule oral therapeutic to prevent and reverse skeletal muscle atrophy in aging adults - limited… | National Institute on Aging | $644,864 | |
| Preclinical development of a novel therapeutic to rejuvenate aging muscle stem cells and enhance muscle strength and… | National Institute on Aging | $9,645,577 | |
| Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat duchenne… | National Insititue of Arthritis and Musculoskeletal and Skin Diseases | $252,131 |
About Ridgeline Therapeutics, Inc.
Ridgeline Therapeutics LLC is a Houston-based biotechnology company focused on developing innovative small molecule therapeutics targeting muscle health, aging, and metabolic conditions. Registered in SAM.gov since 2012, the company specializes in research and development of novel pharmaceutical interventions, with a particular emphasis on compounds that address muscle degeneration, obesity, and age-related physiological challenges. The company's primary research platform centers on developing small molecule drugs that inhibit nicotinamide N-methyltransferase (NNMT), an enzyme critical for cellular energy metabolism and muscle stem cell activation.
The company has secured multiple federal grant awards from agencies like the National Institute on Aging and the Defense Health Agency, totaling approximately $2.48 million in project grants between 2021 and 2025. These grants support preclinical research on compounds such as RT-002 and RT-001, which aim to prevent muscle loss, enhance weight loss, improve muscle strength, and address conditions like osteoarthritis and disuse-induced muscle atrophy. Specific research objectives include developing therapeutic interventions for older adults, evaluating drug efficacy in diet-induced obesity mouse models, and creating treatments to accelerate muscle regeneration and recovery from injuries. The grants span various research domains, including musculoskeletal injury recovery, muscle stem cell activation, obesity treatment, and potential interventions for age-related muscle degeneration, with a focus on translating preclinical findings into potential clinical treatments for military and civilian populations.
Quick answers
What is Ridgeline Therapeutics, Inc.'s UEI?
Ridgeline Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is KM9RHDLMHTN5.
What is Ridgeline Therapeutics, Inc.'s CAGE code?
Ridgeline Therapeutics, Inc.'s CAGE code is 6PN60.
What is Ridgeline Therapeutics, Inc.'s primary NAICS code?
Ridgeline Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Ridgeline Therapeutics, Inc. located?
Ridgeline Therapeutics, Inc.'s physical address in SAM.gov is 3778 Georgetown St, Houston, TX 77005, USA.
Is Ridgeline Therapeutics, Inc. registered in SAM.gov?
Yes. Ridgeline Therapeutics, Inc.'s SAM.gov registration is active through May 5, 2027.
What is Ridgeline Therapeutics, Inc.'s most recent federal award?
Ridgeline Therapeutics, Inc.'s most recent federal grant award is Preclinical validation of a novel adjunct small molecule drug to prevent muscle loss and enhance weight loss in older… (R44AG092210), from National Institute on Aging, on September 22, 2025.
On GovTribe
See Ridgeline Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors